menu search

ACRS / Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Aclaris Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
WAYNE, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will virtually present a company overview at the H.C. Wainwright Global Investment Conference, which will be available beginning on Tuesday, May 24, 2022 at 7:00 a.m. ET. Management will be available May 23rd throughout the day for virtual 1x1 meetings. Read More
Posted: May 16 2022, 07:00
Author Name: GlobeNewsWire
Views: 103180

ACRS News  

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

By Seeking Alpha
September 28, 2023

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Aclaris Therapeutics is a developer of kinome-based medicines for immune-inflammatory and oncology indications. The company's platform, KINect, helps more_horizontal

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

By The Motley Fool
September 14, 2023

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

An analyst raised his price target on the biotech. He also maintained his buy recommendation on the stock. more_horizontal

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to more_horizontal

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

By Seeking Alpha
July 11, 2023

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be more_horizontal

2 Low-Priced Stocks That Could Make You Richer

By The Motley Fool
June 26, 2023

2 Low-Priced Stocks That Could Make You Richer

Low-priced stocks tend to be more trouble than they are worth. On the rare occasion, however, these equities can turn out to be diamonds in the rough. more_horizontal

Why Aclaris Therapeutics Topped the Market on Tuesday

By The Motley Fool
June 13, 2023

Why Aclaris Therapeutics Topped the Market on Tuesday

The biotech has completed enrollment in the next phase of an important development program. It is aiming to get a rheumatoid arthritis drug to market. more_horizontal

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 8, 2023

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to more_horizontal

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

By GlobeNewsWire
May 2, 2023

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developi more_horizontal


Search within

Pages Search Results: